Human brain transcriptomes can highlight biological pathways associated with Alzheimer's disease (AD); however, challenges remain to link expression changes with causal triggers. We have examined 30 ADassociated, gene coexpression modules from human brains for overlap with 251 differentially-expressed gene sets from mouse brain RNA-sequencing experiments, including from models of AD and other neurodegenerative disorders. Human-mouse overlaps highlight responses to amyloid versus neurofibrillary tangle pathology and further reveal age-and sex-dependent expression signatures for AD progression. Human coexpression modules enriched for neuronal and/or microglial genes overlap broadly with signatures from mouse models of AD, Huntington's disease, Amyotrophic Lateral Sclerosis, and also aging. Several human AD coexpression modules, including those implicated in the unfolded protein response and oxidative phosphorylation, were not activated in AD models, but instead were detected following other, unexpected mouse genetic manipulations. Our results comprise a powerful, cross-species resource and pinpoint experimental models for diverse features of AD pathophysiology from human brain transcriptomes.
INTRODUCTION
Alzheimer's Disease (AD) is a progressive and incurable neurodegenerative disorder, with rapidly increasing prevalence due to population aging (Scheltens et al., 2016) . At autopsy, AD is characterized by extracellular neuritic amyloid plaques and intraneuronal neurofibrillary tangles, comprised of misfolded and aggregated Amyloid-Beta (Aβ) peptide and the Microtubule Associated Protein Tau (MAPT/Tau), respectively. Based on RNA sequencing (RNA-Seq) from 2,114 human postmortem brain samples, the Accelerating Medicines Partnership-Alzheimer's disease (AMP-AD) consortium has identified 30 coexpression modules significantly associated with AD clinical-pathologic diagnosis (Logsdon et al., submitted) . These data show promise to highlight completely unexpected molecular insights into AD pathogenesis; however, interpretation is hindered by several obstacles. One major challenge arises from the recognition that the AD pathologic cascade initiates decades prior to 3 onset of clinical manifestations Jack et al., 2013) , whereas human brain expression profiles can only be generated cross-sectionally at the time of death. Indeed, it is essential to reconstruct the longitudinal, aging-dependent time-course of molecular derangements in order to pinpoint the earliest possible opportunities for intervention and to develop effective biomarkers. Second, most brains from older persons with AD show mixed pathologies at autopsy, including many other age-related lesions associated with cognitive impairment (Kapasi et al., 2017) . Therefore, functional dissection of human coexpression modules requires differentiating specific causal triggers, including (i) AD lesions (Aß plaques and/or Tau tangles), (ii) other neuropathology, or (iii) brain aging more generally. Lastly, even following the most comprehensive analysis, it remains challenging to determine which gene expression changes associated with disease are truly primary and therefore causal, rather than simply a consequence of AD.
By contrast with studies of human postmortem tissue, mouse models allow for controlled experimental manipulations to isolate the effects of specific molecular lesions, investigate for dynamic, age-dependent changes, and definitively establish causation. A large number of AD mouse models have been extensively characterized, and these systems have already contributed enormously to our understanding of disease pathogenesis (Götz and Ittner, 2008; Jankowsky and Zheng, 2017; LaFerla and Green, 2012) . The most widely used transgenic models express mutant forms of the amyloid precursor protein (APP) gene, with or without presenilin-1/2 (PSEN1/2), which are associated with autosomal dominant, early-onset AD; or alternatively, MAPT mutations, which cause familial frontotemporal dementia (FTD). These models recapitulate features of AD neuropathology, including plaques or tangles, along with variable degree of neuronal dysfunction/loss, and progressive neurobehavioral impairments (Ballatore et al., 2007; Esquerda-Canals et al., 2017) . More recently, gene expression profiling, including RNA-seq, has been applied to elucidate brain transcriptome signatures. Among the results, these investigations have highlighted the importance of immune/inflammatory and neuronal/synaptic changes (Boisvert et al., 2018; Cummings et al., 2015; Gjoneska et al., 2015; Matarin et al., 2015; Rothman et al, 2018; Stephenson et al., 2018; Swartzlander et al., 2018) . While some reports have identified selected 4 overlaps between expression changes in AD mouse models and human brains (Bennett et al., 2018a; Castillo et al., 2017; Mostafavi et al., 2018; Neuner et al., 2019; Rojo et al., 2017) , other studies have questioned the overall degree of conservation (Burns et al., 2015; Galatro et al., 2017; Hargis and Blalock, 2017) .
The goal of this study is to systematically define correspondences between gene expression changes associated with AD in human brains and those caused by controlled experimental manipulations in mouse models. In addition to the brain RNA-seq datasets available from mouse models of AD, our cross-species analysis takes advantage of hundreds of other experimental comparisons relevant to diverse neurologic disorders, brain health, and aging. Our results highlight strengths and limitations among currently available AD models, and enhance understanding of the causes and consequences for gene expression signatures in human brains.
RESULTS
To enable cross-species comparisons of brain transcriptome data, we reprocessed brain RNA-Seq data from 96 distinct mouse studies relevant to AD, other neurodegenerative disorders, aging and related mechanisms (Figure 1 and Table S2 , Methods), and curated 376 unique experimental comparisons (genetic manipulation vs. control condition). The resulting 251 sets of significant DEGs (gene membership >10, fold-change > 1.2, FDR < 1%) define brain "gene expression signatures" (mean = 1385 genes, range = 10 -12,393) characteristic of the respective mouse model comparisons (Table S3 and Supplemental Files). These expression profiles encompass 25,181 unique genes out of 52,873 total in the mouse transcriptome. As visualized using the t-SNE algorithm ( Figure 1C ), the curated expression signatures capture a combination of disease-specific and overlapping features characteristic of the heterogeneous mouse models included in this study. Even among mouse models for the same disease category, the overall extent of gene sharing among the corresponding sets of DEGs was modest ( Figure   S1 ); therefore, the included comparisons sample a wide spectrum of brain transcriptional responses. We next evaluated the overlap between each mouse expression signature and 30 human AD-associated brain 5 coexpression modules, based on analyses of human postmortem brain RNA-seq from AMP-AD (Table   S1 ) (Logsdon et al, submitted) . Overall, we detect 1,569 significant overlaps (p adj < 0.01), with the majority (68%) of experimental models showing evidence for gene expression changes corresponding to multiple human modules (mean = 6 overlapping modules per mouse model DEG set) ( Figure 2 ). As expected, since human coexpression modules derived from different brain regions demonstrate extensive gene sharing, many mouse DEG sets show consistent overlaps within "module clusters" consisting of overlapping gene sets similarly enriched for neuronal, microglial, astrocytic, oligodendroglial, and/or endothelial expression signatures (Logsdon et al., submitted) . We next assessed the direction of gene expression changes in mouse and human brains. The majority (77%) of overlapping gene expression signatures are concordant across species (Figure 2 ). For example, module clusters enriched for microglial genes are up-regulated in brain transcriptomes from human AD and mouse models, whereas those enriched for neuronal genes are predominantly down-regulated, but with notable exceptions (Figure 2 & Figure 3C ). Lastly, 28 out of 30 modules significantly overlap (p adj < 0.01) with at least 1 mouse model expression signature. In sum, these results support broad conservation of gene regulatory systems in the mammalian brain, and highlight that many AD-associated brain expression patterns are recapitulated in available mouse experimental models.
We next systematically examined whether available mouse models of AD show gene expression changes similar to those detected in human AD brains ( Figure 3A) . Our reprocessed dataset includes 53 expression signatures from 12 distinct AD transgenic models, including numerous APP and MAPT transgenic strains. Human microglial-and neuronal-enriched coexpression modules strongly overlap with expression signatures from mouse AD models ( Figure 3A-C) . For example, the microglial-enriched FPturquoise module overlaps significantly (p adj < 1x10 -5 ) with the majority of expression signatures from both APP (66%) and MAPT (67%) mouse models. While overlaps with the neuronal-enriched modules, such as PHGbrown, were more restricted, this pattern was still observed in a substantial proportion of models (22% and 25% of APP and MAPT models, respectively). In most cases, the attenuation of gene 6 expression from neuronal modules and activation of microglial-enriched signatures appears to be mutually exclusive. Interestingly, coincident changes in both neuronal and microglial modules ( Figure   3A , circles) was characteristic of selected MAPT transgenic strains, and was also seen in the CDK5-P25 mouse which similarly develops extensive Tau pathology and brain atrophy (Cruz et al., 2003) . This coincident microglial/neuronal overlap pattern is only rarely seen among expression signatures from the APP models (1 out of 34 DEG sets). We also considered overlaps in relation to the level of pathologic burden previously reported in each APP or MAPT model ( Figure 3A) . Overall, mouse expression signatures exhibited strong overlaps with microglial-enriched human modules at later, more severe stages of brain pathology. Reciprocally, neuronal module overlaps characterized models with earlier and comparatively mild pathologic burden. RNA-seq profiles generated from multiple aged timepoints permit examination of dynamic changes in human overlap patterns for selected AD models ( Figure 3B ). For example, in the TgCRND8 APP transgenic mouse, microglial module activation is seen by 6-months, and this signature is sustained in evaluations at 12-months (M248, M250, and M251; Figure 3A , cross-hatches and Figure 3B , top). By contrast, in the rTg4510 MAPT mouse model, transient gene expression changes overlapping neuronal-enriched human modules either preceded or accompanied the appearance of microglial expression signatures (M239-M244; Figure 3A , arrowheads, and Figure 3B , bottom). In addition, when compared to males, female rTg4510 mice revealed accelerated progression in brain transcriptional changes ( Figure 3B , bottom), consistent with a sex by age interaction. Compared with the microglial-and neuronal-enriched module clusters, overlaps between AD mouse model expression signatures and astrocytic, oligodendroglial, and/or endothelial-enriched modules were more sparsely detected ( Figure 3A ). For example, TCXyellow and STGyellow-two modules similarly enriched for oligodendroglial markers and implicated in sphingolipid metabolism-showed selective overlap with aged APP transgenic models (e.g. TgCRND8 (M247), 5xFAD (M223), APPPS1 (M3) and PS2APP (M145); Figure 3A , squares, and Figure S2 ). In sum, our cross-species analyses highlight significant overlaps between transcriptional responses in AD mouse models and human postmortem brains, and 7 pinpoint those expression signatures denoting age-and sex-dependent disease progression as well as Aß-versus Tau-pathology.
Numerous mechanistic parallels have been recognized between AD and other neurodegenerative disorders, including similar protein aggregate pathologies, proteostatic and oxidative stress, neuroinflammation, and the critical role of aging in disease risk and/or progression (Block and Hong, 2005; Bucciantini et al., 2002; Guo and Lee, 2014; Haass and Selkoe, 2007; Nixon, 2005; Ross and Poirer, 2004) . We therefore examined potential overlap between human AD coexpression modules and ) and other modules implicated in inflammation and immunity. As discussed below, this result suggests that these patterns may not be specific for disease states but rather may accompany brain aging more generally. We therefore examined for any human coexpression modules with overlap profiles showing relative specificity for AD models. While none show absolute specificity, we found that modules enriched for oligodendroglial markers, including FPblue and TCXyellow are strongly activated in selected AD models (e.g. M145,
M247, M223, M65 in Figure 3 ) but show comparatively sparse or weaker overlap with expression signatures from the majority of other disease models. Thus, these modules may highlight transcriptional programs that are preferentially activated by AD pathophysiology, such as Aß neurotoxicity.
Our analyses also considered many additional mouse genetic manipulations based on potential relevance to neurodegenerative mechanisms ( Figure Autosomal dominant mutations in neuroserpin cause familial encephalopathy with neuroserpin inclusion bodies, a rare, young-onset neurodegenerative dementia caused by protein aggregation within the endoplasmic reticulum and associated ER stress (Roussel et al., 2013) . Figure   4B , p adj =5.4x10 -9 ) that is enriched for genes involved in oxidative phosphorylation and mitochondrial translation. Interestingly, Gnas, which encodes a G-protein alpha stimulatory subunit, is a complex, imprinted genomic locus implicated in hypothalamic control of energy balance. Loss of the Gnasxl isoform causes a hypermetabolic mouse phenotype, resulting in growth retardation, hypoglycemia, and reduced adiposity (Nunn et al., 2013) .
DISCUSSION
Mouse genetic models have contributed enormously to our understanding of AD pathophysiology (Ballatore et al., 2007; Esquerda-Canals et al., 2017) ; however, the utility of these mice as robust preclinical models for AD has been challenged (Drummond and Wisniewski, 2017; Onos et al., 2016; Sasaguri et al., 2017) . First, most AD mouse models are based on rare forms of familial autosomal dominant AD, which are caused by single, highly penetrant gene mutations. By contrast, late-onset AD arises from dozens of other risk variants, including many with modest effect sizes (Karch et al., 2014; Lambert et al., 2013; Sims et al., 2016) , perhaps in combination with non-genetic risk factors. Second, unlike mouse models, most brain autopsies from individuals with AD show evidence of heterogeneous, mixed pathologies which likely modify disease onset, manifestations, and progression. Third, it has been 1 0 suggested that widely used mouse neurobehavioral assays may be poor predictors of clinically relevant outcomes in human AD. In this study, we use the brain transcriptome to examine the correspondence between 30 human AD brain gene expression networks and 251 mouse experimental comparisons. These analyses provide a systems-level view of the molecular overlap between AD in humans and mouse models, as represented in the brain transcriptome.
Our results show that many AD transgenic mice, including both APP and MAPT models, show differential expression signatures that significantly overlap with AD-associated coexpression modules from human brains. The most robust overlaps were detected among module clusters strongly enriched for neuronal and microglial genes. However, these modules account for only 14 out of 30 total coexpression networks (47%), and as discussed further below they do not appear to be specific for AD. By contrast, a second group of human modules, especially those enriched for oligodendroglial genes, show comparatively greater specificity for AD, albeit for a rather restricted subset of models. Lastly, a substantial minority of AD-associated human brain coexpression modules had virtually no detectable overlap with available AD mouse models. The overlaps we define highlight those molecular features of AD biology recapitulated in existing AD mouse models, whereas non-overlapping modules may identify aspects of AD pathophysiology poorly captured. We conclude that most AD mouse models show overall poor correspondence to human disease, based on brain transcriptomes, with exception of neuronal/microglial-enriched modules. This is an important caveat for interpretation of studies using these animal models, and may explain in part their poor predictive power as AD preclinical models. Our findings are consistent with a complementary study of mouse data from gene expression arrays (Hargis and Blalock, 2017) . Since the overall correlation of the brain transcriptome and proteome is modest (Seyfried et al., 2017) , it will be important in future work to consider whether human-mouse gene expression overlaps are improved at the protein level.
Our analyses also highlight the value of experimental models for interpretation of human brain transcriptome profiles. Analyses considering either cross-sectional or longitudinal datasets similarly suggest that transcriptional changes overlapping human brain neuronal-enriched modules may represent 1 1 an earlier, transient stage of AD, whereas microglial signatures are a subsequent and more sustained AD endophenotype. These results are consistent with other studies of AD mouse model transcriptomes reporting changes in neuronal-and microglial-enriched gene pathways (Cummings et al., 2015; Gjoneska et al., 2015; Matarin et al., 2015) . Additionally, human brain astrocytic and oligodendroglial modules overlap with differential expression signatures from CDK5-P25 and 14 month-old 5xFAD models, which are both notable for their advanced pathologic changes, potentially consistent with a comparatively endstage AD transcriptional endophenotype. Transition points between human-mouse overlaps can be linked to the manifestation of disease-relevant mouse phenotypes. For example, CRND8 APP mice manifest reduced synaptic markers and hippocampal neuronal loss at 6 months, when overlaps are first detected with microglial modules (Adalbert et al., 2009; Brautigam et al., 2012) . Similarly, in Tg4510 MAPT transgenic animals evaluated at 4 and 6 months, respectively, memory task impairment and subsequent neurodegenerative pathologic changes correspond to sequential activation of neuronal and microglial expression patterns (Blackmore et al., 2017; Ramsden et al., 2005) . Since human brain RNA-seq can only be evaluated at the time of death, there are significant challenges to resolve age-dependent changes or to definitively establish links with clinical-pathologic progression. Collection of AD mouse RNA-seq from additional timepoints may therefore accelerate discovery of improved molecular biomarkers of AD progression, and ultimately pinpoint critical windows for therapeutic interventions. Our cross-species approach additionally highlights sex-dependent changes, suggesting that female mice manifest a more rapid progression based on gene expression profiles, consistent with prior observations in both mice (Jiao et al., 2016) and human epidemiology (Altmann et al., 2014; Li and Singh, 2014; Mayeux and Stern, 2012) . The apparent age by sex interaction recapitulated by our human-mouse comparisons is consistent with the companion report by Logsdon et al. (submitted) , and underscores the substantial impact of sex on the brain transcriptome in AD.
Aging is the strongest known AD risk factor, and as highlighted above, is also a potent modifier of the transcriptome in AD mouse models. Using a distinct analytic design and largely independent datasets, Hargis and Blalock (2016) reported that DEGs were concordant between aging in humans and 1 2 rodent models, a conclusion supported by our analysis. Strikingly, the majority of AD-associated human brain coexpression modules showing overlaps with APP and/or MAPT transgenic mouse models, were also seen in aged, wild-type mice, as well as many other disease models. This result suggests that many human brain gene expression changes associated with AD, including neuronal-and microglial-enriched modules reported in other studies (Mostafavi et al. 2018; Zhang et al. 2013) , may represent common transcriptional programs activated by the aging process itself. Rather than representing a specific signature of AD pathophysiology (e.g. Aß-or Tau-mediated mechanisms), these pathways appear to be triggered and/or accelerated by heterogeneous triggers, including those manipulated in mouse models of HD, ALS, SCA1 and other neurodegenerative disorders. Interestingly, several module overlap patterns still revealed possible disease-specific signatures. For example, several modules enriched for oligodendroglial markers showed comparatively selected overlap AD models, particularly APP transgenic models, and related human brain coexpression networks have previously been implicated in AD in multiple studies McKenzie et al. 2017; Mostafavi et al. 2018) . Alternatively, coincident activation of both neuronal-and microglial-enriched modules was seen preferentially in models characterized by significant Tau pathologic burden. In contrast to AD and other neurodegenerative disease models, nearly all differential expression signatures from HD mice (35 out of 37) did not significantly overlap with microglial-enriched coexpression modules ( Figure S4 ).
Our study has several notable limitations. The large size of most human coexpression modules may limit sensitivity to detect significant overlaps using the hypergeometric test, especially for functional pathways represented by smaller gene sets. Compared to the laboratory preparation of mouse mRNA, the extraction and processing of human brain tissue is likely more susceptible to postmortem artefact, although AMP-AD analyses adjusted for sample variability in postmortem interval (Logsdon et al., submitted) . Moreover, the human RNA-seq data, along with the majority of included mouse studies, derive from bulk brain tissue, which includes mixed cell types. Indeed, most of the AMP-AD coexpression modules are strongly enriched for cell-type specific signatures, which may therefore reflect global changes in cell proportions, such as neuronal loss or microglial infiltration. We anticipate that the 1 3
increasing availability of single cell expression profiles will definitively address this concern. In addition, since the extent and tempo of neurodegeneration, including in both human and mouse models, can vary widely across different brain regions, RNA-seq profiles from whole brain might obscure more localized transcriptome overlaps. Lastly, while we selected nearly 100 independent mouse RNAseq studies for inclusion in our analyses, prioritizing those most relevant to AD and neurodegeneration, we omitted many others with the potential to provide additional insights. In the future, our approach can thus be generalized to examine overlaps with an even broader sample of available mouse data.
The strengths of our study include consideration of a still large and diverse number of mouse studies and the use of a single RNAseq-reprocessing pipeline to facilitate cross-model comparisons. We also leveraged AMP-AD coexpression modules based on analyses of more 2,000 human brains and representing consensus networks derived from 5 independent algorithms. Importantly, unlike comparisons based on pathology or behavioral phenotypes, brain expression profiles likely represent more proximal endophenotypes, potentially affording greater sensitivity and reliability for detection of cross-species overlaps. In fact, we highlight several overlaps with transcriptomic endophenotypes from completely unexpected mouse experimental manipulations which manifest brain expression changes that mimic human AD, and in some cases even overlap modules better than currently available AD mouse models. Such "AD transcriptologs"-mouse models based on transcriptome homology-may pinpoint non-obvious experimental models for future investigation of AD pathophysiology.
METHODS

Human coexpression modules
The derivation of 30 AD-associated human coexpression modules is described in the companion report from AMP-AD (Logsdon et al., submitted) (doi: 10.7303/syn11932957.1). Briefly, the consensus networks are based on RNA-Seq data from 2114 total postmortem brain samples from 3 independent cohorts, including the Religious Order Study and the Memory and Aging Project (syn3388564) (Bennett et al., 2018; Mostafavi et al., 2018) , the Mount Sinai Brain Bank (syn3157743) , and 1 4
the Mayo clinic (syn5049298, syn3163039) (Allen et al., 2016; Allen et al., 2018) . Postmortem tissue was collected from seven distinct brain regions: dorsolateral prefrontal cortex (DLPFC); temporal cortex (TCX) and cerebellum (CBE), and inferior frontal gyrus (IFG), superior temporal gyrus (STG), frontal pole (FP), and parahippocampal gyrus (PHG). Five distinct algorithms were used to independently generate coexpression networks from each brain region, and graph clustering was subsequently applied to all modules enriched for AD-differentially expressed genes, leading to 30 aggregate modules (Table S1 ). Figure 1 depicts the overall analysis pipeline for collecting and processing mouse studies, and examining overlaps with human coexpression modules. A total of 96 studies, encompassing data from 2279 mouse tissue samples, were analyzed (Table S2 ). These data were collected from three sources: the Gene Expression Omnibus (GEO) database (83 studies), the AMP-AD Knowledge portal (syn5550383) (6 studies), and through personal communication (7 studies). We searched the GEO database on September 12, 2017 using the keywords "brain", "mouse", and "expression profiling by high throughput sequencing", identifying 881 studies for initial consideration. All studies were next indexed using high frequency terms, and secondary filtering was based on manually curated keywords relevant to AD pathophysiology (Karch et al., 2014) (Table S2) . Lastly, the filtered list of 349 studies was reviewed by the study team. We excluded studies, or in some cases specific samples, involving (1) tissue source other than nervous system, (2) organisms other than mouse, or (3) non-coding RNA. From the remainder, 79 GEO studies were selected for inclusion based on relevance to AD, neurodegeneration, or related mechanisms. All included studies had publicly available RNA-seq data derived from either mouse brain or brain-derived cell lines. Following these initial searches, we discovered only a single eligible RNA-seq study for analysis of aging-associated expression changes (GSE61915). Given the importance of aging in AD, we identified and included an additional 5 expression array profiling studies related to brain aging. Table S2 details all studies included in this analysis, including data source, citations, and relevant keywords.
Mouse dataset selection
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RNA-seq/microarray re-processing and differential expression analysis:
A unified RNA-seq analysis pipeline (Figure 1 ) was used for reprocessing of all datasets, with the exception of 2 HD studies where count files were downloaded directly from GEO. Data processing leveraged the cloud formation cluster at Amazon Web Services. We first created one EC2 master instance (m3.xlarge) which was used to launch hundreds of EC2 computing nodes (c3.8xlarge). Next, each computing node was assigned to process one sample using our customized RNA-seq pipeline, as implemented using Snakemake v.4.8.0 (Köster and Rahmann, 2012) . For samples in AMP-AD studies, the pipeline begins with downloading BAM files from the AMP-AD Knowledge Portal using the Synapse python client. The BAM files are then converted to fastq files using Picard SamToFastq command v.2.18.2 (http://broadinstitute.github.io/picard). For GEO studies, SRA files were downloaded from the database using the GEOquery R package v.2.42.0 (Davis and Meltzer, 2007) , and fastq files were generated using the fastq-dump command from the NCBI SRA toolkit v2.8.2.1 (Andrews, 2010) .
Alignment to the mouse reference genome GRCm38 (mm10) was implemented using STAR v.2.5.1b (Dobin et al., 2013) , and BAM file reads were subsequently sorted by coordinate using samtools v0.1.5 (Li et al., 2009) . Genes were quantified using either HTSeq v0.6.0 (Anders et al., 2015) or using the 'quantMode' option from the STAR aligner which utilizes HTSeq algorithm and produces similar results.
Results were uploaded to the Synapse portal using the python client. Differential gene expression analysis was conducted using DESeq2 v1.18.1 (Love et al., 2014) . For the limited number of microarray studies, pre-processed intensities available from the series matrix files were downloaded from GEO and normalized using quantile normalization, followed by differential expression analysis using the limma package v3.4.2 (Ritchie et al., 2015) . For each study (Table S3) , experimental and control pairs were manually curated. We required a minimum of n = 2 samples for each group (experimental and control); the average for all samples included in each comparison was n = 8.4 (range = 4-28 total samples).
Overall, 376 mouse experimental comparisons were curated for computation of differentially expressed gene sets (DEGs), applying a false-discovery rate (FDR) threshold of 1% and minimum fold-change of 1 6
1.2. The t-distributed Stochastic Neighbor Embedding (t-SNE) algorithm (Maaten and Hinton, 2008 ) was applied to DEGs from all studies (logarithm-transformed fold-change), using the Rtsne function in R. We excluded all DEG sets from consideration consisting of fewer than 10 conserved mouse genes, resulting in 251 sets of DEGs for consideration in our subsequent analyses. All analysis was done using R v3.4.2, and Python v.2.7.12. Table S3 details all DEG sets meeting these criteria, including data sources.
To facilitate ease of use and repurposing of the data, each mouse DEG set was assigned a unique identifier (M###), and we also developed a descriptive nomenclature for annotation. Each gene set received a label taking the form: category_experimental condition_sex_age_brain region_cell type_ transgene. In this standardized annotation, "category" denotes the relevant neurologic disease (e.g. AD,
HD, SCA, ALS) or "other" for gene manipulations not directly linked to human disease, along with the specific "experimental condition" describing the mouse genotype or treatment condition. We also note "sex" (M or F), "age" (months), and where applicable, "brain region" (e.g. hippocampus), "cell type"
(e.g. neuron, microglia). In the case of AD mouse models, we also annotate "transgene", to differentiate "APP", "Tau" (MAPT), or "other" models. If unknown or not applicable, the relevant field(s) are replaced with "na". These annotations and conventions are used throughout our supplementary tables and files.
Analysis of mouse-human overlaps
Mouse orthologs for all human genes were extracted using the HCOP tool available from the HUGO Gene Nomenclature Committee (https://www.genenames.org/cgi-bin/hcop) (syn17010253). Using the hypergeometric test, we determined the significance of overlap between each of 251 mouse DEG sets (above) and the 30 human gene coexpression modules (mouse orthologs) using the phyper function in R (Table S4 ). The Benjamini-Hochberg method was applied to adjust for multiple comparisons, using the p.adjust function. All p-values reported in the text were adjusted in this manner. Overlap significance was visualized using heatmaps, implemented with pheatmap function in R, using Manhattan distance (for both rows and columns) and Ward clustering. In order to determine whether mouse-human overlapping genes 1 7 also shared expression changes in the same direction, we computed the concordance score for each overlap. The direction of change for human genes was extracted from the data in Logsdon et al.
(submitted) (syn14237651). Specifically, the concordance score is the percentage of genes in the concordant direction weighted by the significance based on the hypergeometric test, which is computed as follows:
, where
The overlap was considered concordant when the weighted concordance is greater (or less) than half standard deviation from the median, and p adj ≤ 0.01 for the up-or down-differential expression. and resulting overlaps can be found in Table S3 and S4. for all models, including sample sizes for all comparisons, and resulting overlaps can be found in Table   S3 including sample sizes for all comparisons, and resulting overlaps can be found in Table S3 and S4. For complete heat maps representing overlaps with HD, FTD-ALS, SCA1, and aging models, see Figure S4 -6. (B) Representative overlaps of human modules with mouse DEGs, as in Figure 3C .
DATA AND SOFTWARE AVAILABILITY
Data from this study, including all re-processed RNA-seq from mouse models, subsequent differential expression analysis, and the overlap analyses with human coexpression modules is available from the AMP-AD Knowledge Portal at doi:10.7303/syn16779040.
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